Chris Boshoff, MD, PhD
Frontline maintenance therapy with avelumab (Bavencio) plus best supportive care demonstrated a statistically significant improvement in overall survival (OS) compared with best supportive care alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression, meeting the primary endpoint of a planned interim analysis of the phase III JAVELIN Bladder 100 study (NCT02603432).1
The PD-L1 inhibitor demonstrated the survival benefit in both coprimary patient populations, which were all randomized patients and those with PD-L1–positive tumors. Additionally, the safety profile with avelumab was found to be consistent with previous trials of the immunotherapy.
... to read the full story